Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $257.8 million.

  • ImmunityBio's Cash & Current Investments rose 9775.94% to $257.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $257.8 million, marking a year-over-year increase of 9775.94%. This contributed to the annual value of $149.8 million for FY2024, which is 4377.85% down from last year.
  • As of Q3 2025, ImmunityBio's Cash & Current Investments stood at $257.8 million, which was up 9775.94% from $153.7 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Cash & Current Investments peaked at $317.1 million during Q4 2021, and registered a low of $46.0 million during Q2 2023.
  • Moreover, its 5-year median value for Cash & Current Investments was $130.4 million (2024), whereas its average is $148.1 million.
  • As far as peak fluctuations go, ImmunityBio's Cash & Current Investments tumbled by 6620.04% in 2022, and later soared by 37434.17% in 2024.
  • Quarter analysis of 5 years shows ImmunityBio's Cash & Current Investments stood at $317.1 million in 2021, then plummeted by 66.2% to $107.2 million in 2022, then skyrocketed by 148.6% to $266.5 million in 2023, then crashed by 43.78% to $149.8 million in 2024, then skyrocketed by 72.09% to $257.8 million in 2025.
  • Its Cash & Current Investments stands at $257.8 million for Q3 2025, versus $153.7 million for Q2 2025 and $61.6 million for Q1 2025.